80% of Patients with Breast Cancer That Has Spread to the Skin Respond to Adgero’s REM-001 Therapy

80% of Patients with Breast Cancer That Has Spread to the Skin Respond to Adgero’s REM-001 Therapy
Eighty percent of certain patients with breast cancer that has spread to the skin respond to REM-001 Therapy, which involves a laser and a compound, according to the developer, Adgero Biopharmaceuticals. The category of patients who benefited were those with cutaneous metastatic breast cancer whose previous radiation therapy had failed, Adgero said. They responded whether or not they were also receiving chemotherapy or hormone therapy, it added. Adgero Vice President Steve Rychnovsky presented the findings at the American Society for Laser Medicine and Surgery 2017 Annual Conference in San Diego. The presentation was titled "Synergistic Effect of Simultaneous Chemotherapy and Photodynamic Therapy." When breast cancer therapies fail, patients can develop metastatic breast cancer. Cutaneous metastatic breast cancer shows up in nearly 24 percent of breast cancer patients, evidence suggests. It occurs when breast cancer tumor cells travel to the skin and form a new tumor. The skin tumor can come decades after the initial breast cancer diagnosis and treatment. REM-001 Therapy is known as a photodynamic therapy because it includes light. There are three parts to REM-001 Therapy: a laser light source, a light delivery system, and the drug REM-001. The first step in the treatment is injecting REM-001 into a patient's bloodstream, which can convey it to the tumor. Then, a physician uses a fiber-optic wand to illuminate the tumor. Because the drug is photosensitive, it is activated only at the tumor site, reducing the possibility of severe side effects. Adgero conducted four Phase 2/3 clinical trials of REM-001
Subscribe or to access all post and page content.